Disclaimer

The alfapump® system is currently not approved in the United States or Canada. In the United States and Canada, the alfapump® system is currently under clinical investigation (POSEIDON Study) and is being studied in adult patients with refractory or recurrent ascites due to cirrhosis. DSR® therapy is still in development and it should be noted that any statements regarding safety and efficacy arise from ongoing pre-clinical and clinical investigations which have yet to be completed. There is no link between the DSR® therapy and ongoing investigations with the alfapump® system in Europe, the United States or Canada.

Tag

Regulated
PRESS RELEASE REGULATED INFORMATION 20 November 2024, 07:00 am CET Ghent, Belgium – 20 November 2024 – Sequana Medical NV (Euronext Brussels: SEQUA) (the “Company” or “Sequana Medical“), a pioneer in the treatment of fluid overload in liver disease, heart failure and cancer, today invites the holders of securities issued by the Company to attend...
Read More
PRESS RELEASE REGULATED INFORMATION 14 November 2024, 18:00 CET Ghent, Belgium, 14 November 2024 – Sequana Medical NV (Euronext Brussels: SEQUA) (the “Company” or “Sequana Medical“), a pioneer in the treatment of fluid overload in liver disease, heart failure and cancer, announces today that in the context of a contribution in kind of receivables outstanding...
Read More
PRESS RELEASE REGULATED INFORMATION 21 October 2024, 06:00 p.m. CEST Ghent, Belgium, 21 October 2024 – Sequana Medical NV (Euronext Brussels: SEQUA) (the “Company” or “Sequana Medical“), a pioneer in the treatment of fluid overload in liver disease, heart failure and cancer, announces today that in the context of a subscription to new shares by...
Read More
PRESS RELEASE Regulated information 10 October 2024, 17:40 pm CEST Ghent, Belgium – 10 October 2024 – Sequana Medical NV (Euronext Brussels: SEQUA) (the “Company” or “Sequana Medical“), a pioneer in the treatment of fluid overload in liver disease, heart failure and cancer, announces today that it received a transparency notification from the party listed...
Read More
alfapump® – US FDA approval anticipated Q1 2025 and US launch planned for H2 2025; Strong progress with US reimbursement – CPT III codes issued & NTAP Application filed DSR® – Publication of RED DESERT and SAHARA data in peer-reviewed “European Journal of Heart Failure” highlights potential as treatment for Cardiorenal Syndrome;  Positive data from...
Read More
PRESS RELEASE REGULATED INFORMATION 9 August 2024, 07:00 CEST Ghent, Belgium – 9 August 2024 –Sequana Medical NV (Euronext Brussels: SEQUA) (the “Company” or “Sequana Medical“), a pioneer in the treatment of fluid overload in liver disease, heart failure and cancer, announces today that it received a transparency notification from the party listed below, notifying...
Read More
PRESS RELEASE REGULATED INFORMATION 5 August 2024, 06 pm CEST Ghent, Belgium – 5 August 2024 – Sequana Medical NV (Euronext Brussels: SEQUA) (the “Company” or “Sequana Medical“), a pioneer in the treatment of fluid overload in liver disease, heart failure and cancer, announces today that it received a transparency notification from the party listed...
Read More
PRESS RELEASE REGULATED INFORMATION 1 August 2024, 06:30 pm CEST Ghent, Belgium – 1 August 2024 – Sequana Medical NV (Euronext Brussels: SEQUA) (the “Company” or “Sequana Medical“), a pioneer in the treatment of fluid overload in liver disease, heart failure and cancer, announces today that it received a transparency notification from the parties listed...
Read More
Transparency Notifications from Shareholders Ghent, Belgium – 19 July 2024 – Sequana Medical NV (Euronext Brussels: SEQUA) (the “Company” or “Sequana Medical“), a pioneer in the treatment of fluid overload in liver disease, heart failure and cancer, announces today that it received a transparency notification from the shareholder listed below, notifying the number of voting...
Read More
PRESS RELEASE REGULATED INFORMATION 10 July 2024, 06:00 p.m. CEST Ghent, Belgium, 10 July 2024 – Sequana Medical NV (Euronext Brussels: SEQUA) (the “Company” or “Sequana Medical“), a pioneer in the treatment of fluid overload in liver disease, heart failure and cancer, announces today that in the context of the confirmation of the contribution in...
Read More
1 2 3 9

PRESS RELEASES

SUBSCRIBE TO OUR PRESS RELEASES